Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) was upgraded by stock analysts at Wedbush to a "strong-buy" rating in a research note issued on Wednesday,Zacks.com reports.
A number of other equities analysts have also recently commented on the stock. TD Cowen started coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set a "buy" rating for the company. Rodman & Renshaw began coverage on shares of Bicara Therapeutics in a report on Tuesday, November 5th. They set a "buy" rating and a $48.00 target price for the company. RODMAN&RENSHAW raised shares of Bicara Therapeutics to a "strong-buy" rating in a report on Tuesday, November 5th. Cantor Fitzgerald began coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set an "overweight" rating for the company. Finally, Stifel Nicolaus assumed coverage on Bicara Therapeutics in a research report on Tuesday, October 8th. They issued a "buy" rating and a $47.00 target price on the stock. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $41.20.
View Our Latest Analysis on Bicara Therapeutics
Bicara Therapeutics Price Performance
Shares of Bicara Therapeutics stock traded up $0.86 during trading on Wednesday, hitting $12.99. 311,469 shares of the stock were exchanged, compared to its average volume of 364,606. Bicara Therapeutics has a 1-year low of $11.10 and a 1-year high of $28.09. The stock has a fifty day moving average of $15.66.
Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.46) by ($1.14). As a group, analysts expect that Bicara Therapeutics will post -2.59 EPS for the current year.
Hedge Funds Weigh In On Bicara Therapeutics
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Spire Wealth Management bought a new stake in Bicara Therapeutics during the fourth quarter worth about $31,000. SG Americas Securities LLC bought a new stake in shares of Bicara Therapeutics during the 4th quarter worth approximately $147,000. Cinctive Capital Management LP acquired a new stake in shares of Bicara Therapeutics during the 3rd quarter worth approximately $229,000. Barclays PLC bought a new position in Bicara Therapeutics in the third quarter valued at approximately $255,000. Finally, Jane Street Group LLC acquired a new position in Bicara Therapeutics during the third quarter valued at approximately $309,000.
About Bicara Therapeutics
(
Get Free Report)
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
Further Reading
Before you consider Bicara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicara Therapeutics wasn't on the list.
While Bicara Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
